Share Monday, February 25, 2013, 10:15am-12:20pm PST The focus of this session will be the use of expression systems to significantly accelerate development and eventual commercialization of protein therapeutics. Talks might include discussion of current use (or potential use) of novel expression systems for this purpose, or the use of conventional expression systems in a different manner to achieve acceleration. Session Co-Chairs: Tim Charlebois, PfizerThomas Ryll, Biogen Idec Confirmed SpeakersArvia Morris, Amgen: Efficient upstream process development programs generated using early molecule assessment and culture of continuous improvementAmy Shen, Genentech: Past and Present Strategies, Challenges, and Benefits of Stable Cell Line Development at GenentechMartin Allen, Pfizer: Streamlining the Discovery to Development TransitionRashmi Kshirsagar: Integration of Cell Culture Process Platform and Cell Line Expression Systems to accelerate Biopharmaceutical Development Martin Allen Martin is currently an Associate Research Fellow in the Cell Line Development group at Pfizer in Andover, MA. Prior to joining Pfizer Martin was a member of the Cell Line Development groups at Wyeth, Amgen, and Immunex. Martin holds a PhD in Molecular Biology and completed postdoctoral training at the National Jewish Medical and Research Center in Denver, CO.Read more Rashmi Kshirsagar I am a Principal Engineer in Cell Culture Development. I have a PhD in Chemical Engineering from University of Minnesota, Minneapolis. I have worked in the cell culture field for the past 14 years in industry and academia. Read more Arvia Morris After finishing her post doc work in the laboratory of Lawrence Chasin, Arvia has contributed to upstream process programs for Immunex and Amgen. Her areas of interest include vector development, media development, process implementation and raw material evaluation. Read more Amy Shen Amy is a senior scientist and has worked at Genentech for 19.5 years doing only one job, which is developing CHO stable cell lines for Tox and GMP production.Read more Related Topics: Pharmaceutical Engineering & Drug Delivery
Martin Allen Martin is currently an Associate Research Fellow in the Cell Line Development group at Pfizer in Andover, MA. Prior to joining Pfizer Martin was a member of the Cell Line Development groups at Wyeth, Amgen, and Immunex. Martin holds a PhD in Molecular Biology and completed postdoctoral training at the National Jewish Medical and Research Center in Denver, CO.Read more
Rashmi Kshirsagar I am a Principal Engineer in Cell Culture Development. I have a PhD in Chemical Engineering from University of Minnesota, Minneapolis. I have worked in the cell culture field for the past 14 years in industry and academia. Read more
Arvia Morris After finishing her post doc work in the laboratory of Lawrence Chasin, Arvia has contributed to upstream process programs for Immunex and Amgen. Her areas of interest include vector development, media development, process implementation and raw material evaluation. Read more
Amy Shen Amy is a senior scientist and has worked at Genentech for 19.5 years doing only one job, which is developing CHO stable cell lines for Tox and GMP production.Read more